PFA Pension Forsikringsaktieselskab Purchases New Position in IDEXX Laboratories, Inc. $IDXX

Key Points

• PFA Pension bought a new position of 49,811 shares in IDEXX during Q4—about $33.99 million—while institutional investors collectively own roughly 87.84% of the stock.
• IDEXX beat Q results, reporting $3.08 EPS vs. $2.93 expected and $1.09B revenue (up 14.3% YoY); the shares trade at a market cap of ~$45.1B with a P/E of 43.4 and a 52‑week range of $465–$769.98.
• Insiders have sold ~45,957 shares (~$29.9M) in the past 90 days, even as analysts hold a consensus of "Moderate Buy" with an average price target near $751 amid some recent target cuts.

PFA Pension Forsikringsaktieselskab bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 49,811 shares of the company's stock, valued at approximately $33,987,000. PFA Pension Forsikringsaktieselskab owned approximately 0.06% of IDEXX Laboratories at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of IDXX. Virtus Advisers LLC purchased a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $26,000. Park Place Capital Corp purchased a new stake in IDEXX Laboratories in the 4th quarter worth approximately $29,000. WealthCollab LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter worth approximately $30,000. J.Safra Asset Management Corp purchased a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $31,000. Finally, Salomon & Ludwin LLC purchased a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $35,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $567.46 on Monday. The firm's fifty day moving average price is $589.55 and its 200-day moving average price is $651.34. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The stock has a market cap of $45.07 billion, a P/E ratio of 43.42, a price-to-earnings-growth ratio of 3.45 and a beta of 1.58. IDEXX Laboratories, Inc. has a fifty-two week low of $465.00 and a fifty-two week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion for the quarter, compared to analysts' expectations of $1.07 billion. During the same quarter last year, the company posted $2.53 EPS. The business's quarterly revenue was up 14.3% on a year-over-year basis. On average, equities research analysts expect that IDEXX Laboratories, Inc. will post 14.54 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 2,693 shares of the stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the transaction, the executive vice president owned 19,899 shares of the company's stock, valued at approximately $13,163,984.46. This trade represents a 11.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP George Fennell sold 11,345 shares of the stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the transaction, the executive vice president directly owned 9,823 shares in the company, valued at approximately $6,352,730.56. This represents a 53.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,957 shares of company stock worth $29,862,109 in the last 90 days. Corporate insiders own 0.79% of the company's stock.

Wall Street Analyst Weigh In

IDXX has been the topic of several recent analyst reports. BTIG Research lowered their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating on the stock in a research note on Tuesday, February 3rd. Weiss Ratings restated a "hold (c+)" rating on shares of IDEXX Laboratories in a research report on Monday, April 27th. Stifel Nicolaus lowered their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a "buy" rating on the stock in a research report on Tuesday, March 31st. Barclays lowered their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating on the stock in a research report on Thursday, February 5th. Finally, Citigroup initiated coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a "neutral" rating and a $650.00 price objective on the stock. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.